Every Form 4 that Stoke Therapeutics (STOK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow STOK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STOK filings page.
Stoke Therapeutics, Inc. (STOK) reported that its Chief Medical Officer, Barry Ticho, sold a total of 5,545 shares of common stock on September 1, 2026 in open-market transactions under a Rule 10b5-1 trading plan adopted on November 19, 2025. The sales were executed in multiple trades at weighted average prices within disclosed ranges.
Stoke Therapeutics, Inc. (STOK) reported insider equity activity by its Chief Medical Officer, Barry Ticho. On August 14, 2026, he exercised 10,000 performance stock units, receiving 10,000 shares of common stock at a price of $0.00 per share. On August 18, 2026, the company facilitated issuer-mandated sales of 4,525 and 242 common shares, respectively, to satisfy tax withholding liabilities tied to restricted stock unit vesting, at weighted average prices around $32 per share across specified price ranges.
Stoke Therapeutics, Inc. (STOK) reported insider activity by director Edward M. Kaye, MD. On August 14, 2026, he exercised 26,250 performance stock units, receiving an equal number of common shares and reducing that PSU award to 0. On August 18, 2026, a total of 12,567 common shares were sold in open-market transactions at weighted average prices of $32.01 and $32.47 per share, in each case as an issuer-mandated sale to satisfy tax withholding liabilities related to equity vesting.
Stoke Therapeutics, Inc. (STOK) reported insider equity activity by officer Jonathan Allan (General Counsel & Corporate Secretary). On August 14, 2026, Allan exercised 6,000 Performance Stock Units into 6,000 shares of common stock at a stated price of $0.00 per share, reducing that PSU award balance to zero. The award’s achievement had been certified on August 14, 2025, with half vesting then and the remainder vesting on August 14, 2026, subject to continued service. On August 18, 2026, the broker sold a total of 2,861 common shares in open-market transactions at weighted average prices of $32.01$32.47 per share, in an issuer-mandated sale to satisfy tax withholding liabilities related to restricted stock unit vesting and settlement.
Stoke Therapeutics, Inc. chief medical officer Barry Ticho reported selling 7,176 shares of common stock on August 3, 2026 in two open-market or private transactions, at weighted-average prices of $28.9501 and $29.4539 per share, under a Rule 10b5-1 trading plan adopted on November 19, 2025. The sales occurred in price ranges of $28.36–$29.35 and $29.36–$29.54 per share, respectively.
Stoke Therapeutics, Inc. director Seth Loring Harrison reported 16 bona fide gift transfers on July 16, 2026, moving stock options over 303,190 underlying common shares from his direct holdings to the East Pillar 2026 Irrevocable Trust. The options are fully vested, with exercise prices between $10.90 and $40.37 and expirations from 2029 to 2036. The gifts were made for no consideration and are exempt from short-swing profit liability under Rule 16b-5.
Stoke Therapeutics, Inc. reported that Chief Scientific Officer Thomas McCauley received a grant of stock options covering 225,000 shares of common stock at an exercise price of $29.91 per share, expiring on July 14, 2036. The option vests as to 1/4 of the award on July 15, 2027, and as to 1/48 of the award monthly thereafter, subject to his continued service.
Stoke Therapeutics Chief Medical Officer Barry Ticho reported open‑market sales of company stock. On July 1, 2026, he sold a total of 7,228 shares of Common Stock in two transactions.
The first sale covered 6,728 shares at a weighted average price of $32.615 per share, and the second sale covered 500 shares at a weighted average price of $33.2678 per share. The filing notes these trades were executed under a Rule 10b5-1 trading plan adopted on November 19, 2025, indicating they were pre‑scheduled rather than discretionary.
Stoke Therapeutics, Inc. General Counsel and Corporate Secretary Jonathan Allan reported an open-market sale of Common Stock. On June 16, 2026, he sold 1,457 shares at a price of $29.95 per share. Following this transaction, he directly holds 18,086 shares of Common Stock. The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 10, 2025, indicating the trade was made under a pre-arranged schedule rather than as a discretionary market-timing decision.
Stoke Therapeutics director Arthur Tzianabos received a grant of options for 17,786 shares of common stock. The Director Stock Option has an exercise price of $29.46 per share and expires on June 2, 2036. It will vest in full on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, subject to his continued service.
Stoke Therapeutics director Julie Smith received a new stock option grant. On June 3, 2026, she was awarded options covering 17,786 shares of common stock at an exercise price of $29.46 per share. The options vest in full on June 3, 2027 or the date of the next annual stockholder meeting, subject to her continued service, and expire on June 2, 2036.
Stoke Therapeutics director Arthur A. Levin received a grant of stock options covering 17,786 shares of common stock. The options have an exercise price of $29.46 per share and expire on June 2, 2036. According to the grant terms, the award vests in full on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, contingent on Levin’s continued service.
Stoke Therapeutics director Adrian R. Krainer received a grant of 17,786 stock options to buy common shares at $29.46 each. These Director Stock Options were awarded for compensation, not purchased on the open market, and are held as a direct beneficial interest.
The options vest in full on the earlier of June 3, 2027 or the date of the company’s next annual stockholder meeting, as long as Krainer continues serving the company through that date. Following this grant, he holds 17,786 options covering the same number of common shares, which may be exercised before their expiration on June 2, 2036.
Stoke Therapeutics, Inc. reported that director Edward M. Kaye, MD received a grant of options to acquire 17,786 shares of Common Stock. The options have an exercise price of $29.46 per share and expire on June 2, 2036.
According to the terms, the option vests in full on the earlier of June 3, 2027 or the date of the company’s next annual stockholder meeting, subject to his continued service with the company through that vesting date. This is a compensation-related award rather than an open-market stock purchase.
Stoke Therapeutics director Seth Loring Harrison received a grant of 17,786 stock options. These Director Stock Options give him the right to buy 17,786 shares of common stock at an exercise price of $29.46 per share and are held directly.
The options vest in full on the earlier of June 3, 2027 or the date of Stoke Therapeutics’ next annual stockholder meeting, as long as he continues serving the company through that vesting date. The options expire on June 2, 2036, and this grant represents his full reported option position in this filing. This is a compensation award, not an open‑market stock purchase or sale.
Stoke Therapeutics director Jennifer Burstein received a grant of stock options covering 17,786 shares of common stock. These options have an exercise price of $29.46 per share and expire on June 2, 2036. The filing shows she holds 17,786 derivative securities following this grant. According to the vesting terms, the option will vest in full on the earlier of June 3, 2027 or the date of Stoke Therapeutics’ next annual stockholder meeting, provided she continues serving the company through that vesting date.
Stoke Therapeutics, Inc. Chief Medical Officer Barry Ticho reported an open-market sale of 1,795 shares of common stock at $30.58 per share. After the transaction, he directly holds 34,826 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025, indicating it was scheduled in advance.
Stoke Therapeutics, Inc. chief medical officer Barry Ticho reported an open-market sale of company stock. On May 1, 2026, he sold 2,243 shares of common stock at $32.79 per share. Following this transaction, he directly holds 36,621 shares of Stoke Therapeutics common stock.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Barry Ticho adopted on November 19, 2025. Such plans are designed to allow insiders to sell shares according to a preset schedule, helping separate routine portfolio management from discretionary trading decisions.
Stoke Therapeutics director Clare Kahn received a new stock option award covering 30,782 shares of Common Stock. The option has an exercise price of $32.79 per share and expires in 2036. It vests in 12 equal quarterly installments starting July 1, 2026, contingent on continued service.
Stoke Therapeutics, Inc.’s Chief Medical Officer, Barry Ticho, executed an open-market sale of 1,838 shares of Common Stock. The shares were sold at an average price of $32.66 per share. After this transaction, he continues to hold 38,864 shares directly.
The sale occurred under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person, indicating the transaction was scheduled in advance rather than timed discretionarily.
Stoke Therapeutics general counsel Jonathan Allan sold 9,293 shares of common stock in open-market transactions. The sales occurred on March 20, 2026 at weighted average prices of $33.64 and $34.41 per share under a pre-arranged Rule 10b5-1 trading plan. He continues to hold 19,543 shares directly after these trades.
Stoke Therapeutics, Inc.’s Chief Medical Officer, Barry Ticho, reported an option exercise and related share sales. He exercised a stock option for 1,365 shares of common stock at $2.19 per share and then sold a total of 14,311 shares in open-market transactions at prices between $29.99 and $33.855 per share.
The filing notes that part of the activity was an issuer-mandated sale to cover tax withholding tied to restricted stock unit vesting, and that transactions were executed under a Rule 10b5-1 trading plan adopted on November 19, 2025. Following these transactions, Ticho directly holds 40,702 shares of Stoke Therapeutics common stock, with the reported option now fully vested and exercisable.
Stoke Therapeutics, Inc. Chief Financial Officer Thomas Leggett reported issuer-mandated sales of 4,578 shares of common stock on March 17–18, 2026 to satisfy tax withholding obligations tied to vesting of restricted stock units. The shares were sold in multiple open-market transactions at weighted-average prices generally in the low‑$30s, with individual trades ranging from $30.59 to $33.855 per share. Following these transactions, he directly holds 10,172 shares of Stoke Therapeutics common stock, indicating the activity was a tax-related disposition rather than a complete exit from his equity position.
Stoke Therapeutics Chief Patient Officer Jason Hoitt reported mandated share sales to cover taxes on vested stock units. On March 17–18, 2026, he sold a total of 3,712 shares of common stock in open-market transactions required to satisfy tax withholding obligations. Sale prices were based on weighted averages, with individual trades occurring in ranges between $30.59 and $33.855 per share. After these transactions, he directly holds 10,276 shares, and no remaining stock options or other derivatives are reported.
Stoke Therapeutics, Inc. General Counsel and Corporate Secretary Jonathan Allan reported open‑market sales of 8,895 shares of common stock in multiple transactions on March 17–18. A footnote states these sales were issuer‑mandated to satisfy tax withholding liabilities from vesting restricted stock units. After the transactions, he holds 28,836 shares of common stock directly.
Stoke Therapeutics Chief Patient Officer Jason Hoitt exercised 10,000 restricted stock units into 10,000 shares of common stock. This was a derivative exercise (code M), not an open-market purchase or sale. Following the transaction, he directly owned 13,988 shares of common stock and 30,000 RSUs.
Each RSU converts into one share of common stock upon settlement. The RSU award vests in four equal annual installments beginning on March 15, 2026, subject to his continued service. The reported ownership total also reflects 2,186 shares previously acquired through the company’s employee stock purchase plan.
Stoke Therapeutics Chief Financial Officer Thomas Leggett exercised restricted stock units into common shares in a routine compensation-related transaction. On March 15, 2026, he exercised 14,750 restricted stock units, receiving 14,750 shares of common stock at an exercise price of $0.00 per share.
After the transaction, Leggett directly holds 14,750 shares of common stock and 44,250 restricted stock units. Each RSU represents the right to receive one share of common stock upon settlement, and the award vests in four equal annual installments beginning on March 15, 2026, subject to his continued service with the company.
Stoke Therapeutics, Inc. chief medical officer Barry Ticho reported the vesting and exercise of restricted stock units into common shares. On March 15, 2026, RSU awards covering 33,850 shares of common stock were settled at a price of $0.00 per share.
These RSU awards each represent the right to receive one share of common stock upon settlement and vest in annual 25% installments beginning on March 15, 2024, March 15, 2025, and March 15, 2026, subject to continued service. Following these transactions, Ticho directly holds 53,648 shares of Stoke Therapeutics common stock.
Stoke Therapeutics director Edward M. Kaye, MD, increased his direct equity stake through RSU settlements. On March 15, 2026, he exercised or settled restricted stock units covering 61,750 shares of Common Stock at a stated price of $0.00 per share, reflecting equity compensation rather than open‑market purchases.
The RSU awards vest in annual installments of one quarter of the total shares beginning on March 15, 2024 and March 15, 2025, contingent on continued service. Following these transactions, Kaye directly holds 110,874 shares of Stoke Therapeutics Common Stock.
Stoke Therapeutics, Inc. reported that its General Counsel and Corporate Secretary, Jonathan Allan, exercised restricted stock units and acquired common shares. On March 15, 2026, he exercised derivative awards covering 25,475 restricted stock units, each representing one share of common stock, at an exercise price of $0.00 per unit.
These exercises resulted in the acquisition of 25,475 shares of common stock, bringing his directly held common stock position to 37,731 shares following the transactions. Footnotes explain that each RSU converts into one share and that the RSU awards vest in annual installments beginning on March 15, 2024, March 15, 2025, and March 15, 2026, contingent on continued service.
Stoke Therapeutics director Arthur A. Levin reported an open-market sale of 605 shares of Common Stock at $36.80 per share on March 13, 2026. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025.
After this sale, Levin directly holds 4,237 shares of Stoke Therapeutics common stock and indirectly holds 17,979 shares through the Butler-Levin Revocable Trust, where he serves as trustee.
Stoke Therapeutics Interim Executive Chair Arthur Tzianabos reported an option exercise and share sale involving the company’s common stock. On March 10, 2026, he exercised stock options to acquire 3,955 shares of common stock at an exercise price of $8.33 per share. The same day, he sold 4,355 common shares at a weighted average price of $40.0033 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on August 15, 2025. Following these transactions, he directly holds 31,339 common shares and retains 118,696 stock options that are fully vested and exercisable and expire on March 19, 2034.
Stoke Therapeutics, Inc. director Adrian R. Krainer reported an open-market sale of 33,243 shares of common stock on March 10, 2026 at a weighted average price of $39.7366 per share. After this transaction, he directly holds 283,302 shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 15, 2025, meaning the trades were scheduled in advance rather than timed discretionarily.
Stoke Therapeutics director Adrian R. Krainer sold 7,229 shares of common stock in an open-market transaction on March 2, 2026 at a weighted average price of $39.6618 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on August 15, 2025, and he now holds 316,545 shares directly.
Ticho Barry reported acquisition or exercise transactions in this Form 4 filing.
Stoke Therapeutics’ chief medical officer, Barry Ticho, reported equity awards rather than open‑market trades. He was granted options to purchase 60,000 shares of common stock and 40,000 restricted stock units. The option vests monthly over four years starting March 15, 2026, while the RSUs vest in four annual tranches beginning February 15, 2027, in each case conditioned on continued service.
Stoke Therapeutics reported that Chief Executive Officer Ian F. Smith received new equity awards in the form of options and restricted stock units. He was granted 193,000 employee stock options with an exercise right to buy company shares, which vest monthly over four years starting March 15, 2026, contingent on continued service. He also received 129,000 restricted stock units, each representing a right to one share of common stock, vesting in four annual tranches beginning February 15, 2027, also subject to his continued service.
Leggett Thomas reported acquisition or exercise transactions in this Form 4 filing.
Stoke Therapeutics, Inc. reported that its Chief Financial Officer, Thomas Leggett, received new equity awards. He was granted an option to buy 60,000 shares of common stock at no cost on the grant date, which will vest in monthly installments over four years starting March 15, 2026, contingent on continued service. He also received 40,000 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning February 15, 2027, also conditioned on his continued service.
Stoke Therapeutics reported that Chief Patient Officer Jason Hoitt received new equity awards. He was granted employee stock options covering 72,000 shares at an exercise price of $0.0000 per share and 48,000 restricted stock units, each representing one share of common stock.
The option award vests monthly over four years, beginning with 1/48 of the total on March 15, 2026. The RSU award vests in four equal annual installments, with the first quarter vesting on February 15, 2027, in each case subject to his continued service.
Stoke Therapeutics, Inc. reported that its General Counsel and Corporate Secretary, Allan Jonathan, received new equity awards. On February 17, 2026, he was granted an option to buy 53,000 shares of common stock at an exercise price of $0.00 per share and 35,000 restricted stock units (RSUs).
The option vests as to 1/48 of the total award on March 15, 2026, with an additional 1/48 vesting on each monthly anniversary, as long as he continues serving the company. Each RSU represents the right to receive one share of common stock, with the RSU award vesting in four equal annual installments beginning on February 15, 2027, also subject to continued service.
Stoke Therapeutics, Inc. reported insider equity transactions by its Chief Medical Officer. On December 3, 2025, 10,000 performance stock units were exercised at $0, converting into 10,000 shares of common stock. Part of these shares were sold in issuer-mandated transactions to cover tax withholding tied to vesting of restricted stock units.
On December 4 and 5, 2025, the officer sold blocks of common stock in multiple trades, including 1,373 shares at a weighted average price of $30.7635, 323 shares at $31.3164, 1,673 shares at $31.3304, and 1,989 shares at $31.3453. Some sales were made under a pre-established Rule 10b5-1 trading plan. After these transactions, the officer beneficially owned 19,798 shares of Stoke Therapeutics common stock, held directly.
Stoke Therapeutics, Inc. reported insider equity transactions by a company director. On December 3, 2025, the director exercised 26,250 performance stock units at an exercise price of $0, receiving an equal number of common shares. On December 4 and 5, 2025, portions of these and other shares were sold in several market transactions at weighted average prices ranging from $30.23 to $31.96 per share.
One sale on December 4, 2025 is described as an issuer-mandated sale to cover tax withholding tied to the vesting and settlement of restricted stock units. Additional sales on December 5, 2025 were executed under a Rule 10b5-1 trading plan adopted on December 30, 2024. After all reported transactions, the director directly holds 62,554 shares of Stoke Therapeutics common stock, and no performance stock units remain from the reported award. The underlying award vested in two equal parts on December 3, 2024 and December 3, 2025.
Stoke Therapeutics, Inc. (STOK) director reported an open-market sale of company stock. On 11/24/2025, the reporting person sold 40,472 shares of common stock at a weighted average price of $29.7173 per share, through multiple transactions within a price range of $29.50 to $30.12. After this sale, the director beneficially owned 323,774 shares of Stoke Therapeutics common stock in direct ownership form. The filing notes that the sale was made under a Rule 10b5-1 trading plan that was adopted on August 15, 2025.
Stoke Therapeutics, Inc.$26.6141 per share and 20,682 shares at a weighted average price of $27.3361 per share, in each case coded as an open market sale. After these transactions, the director beneficially owned 364,246 shares of Stoke Therapeutics common stock in direct form.
The filing states that the trades were executed under a Rule 10b5-1 trading plan adopted on August 15, 2025, which is designed to provide an affirmative defense for pre-arranged trading. The prices reported reflect multiple individual trades within stated price ranges, and the reporting person has agreed to provide detailed breakdowns of the prices upon request.
Stoke Therapeutics (STOK) disclosed insider sales by its Chief Medical Officer on 11/03/2025 under a pre‑arranged Rule 10b5-1 trading plan adopted on December 11, 2024. The transactions included 3,776 shares at a weighted average price of $25.2242 (range $24.74–$25.65), 1,455 shares at $26.0206 (range $25.79–$26.50), 600 shares at $27.54 (range $27.40–$27.60), and 100 shares at $29.35.
Following these sales, the reporting person directly beneficially owned 7,195 shares.
Stoke Therapeutics (STOK) reported insider equity grants to its Chief Executive Officer and Director. On 10/08/2025, the reporting person received a stock option to buy 570,000 shares at $30.5 per share, expiring on 10/07/2035. The option vests as to 1/4 on 10/06/2026, then 1/48 monthly thereafter, subject to continued service.
The filing also reports 380,000 RSUs, each representing one share of common stock, vesting 1/4 annually on the sixth day of October, with the first tranche on 10/06/2026, subject to continued service. Ownership form for both awards is listed as direct.
Stoke Therapeutics director Edward M. Kaye reported transactions under a Rule 10b5-1 plan dated 12/30/2024. On 10/08/2025 he exercised a stock option with a $0.6 exercise price to acquire 25,000 shares and simultaneously sold 25,000 shares at $30 per share, leaving him with 49,124 shares beneficially owned. The option is fully vested; original vesting began on 10/17/2018 with monthly vesting thereafter, and the reporting was authorized by an attorney-in-fact on 10/10/2025. The filing indicates these actions were made pursuant to the 10b5-1 trading plan to satisfy the affirmative defense conditions.
Director Edward M. Kaye reported the sale of 42,461 shares of Stoke Therapeutics common stock on 10/03/2025 under a pre-existing Rule 10b5-1 trading plan. The filing shows a weighted-average sale price of $25.0867 (individual trades ranged from $25.00 to $25.30), leaving the reporting person with 49,124 shares beneficially owned after the transactions. The schedule was signed by an attorney-in-fact on 10/07/2025.
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported insider transactions dated 10/03/2025. Under a Rule 10b5-1 trading plan adopted on 12/12/2024, he exercised a stock option to acquire 10,000 shares at an exercise price of $9.15 per share and immediately sold 10,000 shares at a weighted-average price of $25.065 per share. The filings show the reporting person beneficially owned 21,831 shares before the sale and 11,831 shares after the sale; he also holds an option representing 10,000 underlying shares exercisable as of 10/03/2025 that expires on 03/14/2033, leaving 34,800 total shares and equivalents reported as beneficially owned following the transactions.
Stoke Therapeutics insider sale executed under a pre-established plan. Chief Medical Officer Barry Ticho sold 5,343 shares of common stock on 10/01/2025 at a weighted average price of $23.6414, with sale prices ranging from $23.40 to $24.08. After the transactions the reporting person beneficially owned 13,126 shares. The filing notes the trades were made pursuant to a Rule 10b5-1 trading plan adopted on 12/11/2024, and the Form 4 was signed via attorney-in-fact on 10/03/2025.
Arthur A. Levin, Ph.D., a director of Stoke Therapeutics, reported equity awards and ownership changes on Form 4. On 09/30/2025 he became the beneficial owner of 1,211 restricted stock units (RSUs) that represent the right to receive one share each upon settlement. The filing shows these RSUs were recorded with a $0 price and are tied to settlement in common stock.
The report indicates 1,211 shares associated with the RSUs are held directly and that following the reported transaction the reporting person beneficially owned 3,631 shares directly and 17,979 shares indirectly through the Butler-Levin Revocable Trust, where he serves as trustee. The RSU award vests in quarterly 1/4 installments on the last day of March, June, September, and December, subject to continued service, with an indicated settlement date of 12/31/2025 for the reported tranche.